A conjugate from a murine monoclonal antibody that localizes or binds to a tumor-associated antigen (TAG-72).

To determine the extent and location of extrahepatic malignant disease in patients with known colorectal or ovarian cancer.

Elimination pattern with a terminal-phase half-life of 56 6 14 hours. About 10% of the administered radioisotope dose is excreted in the urine during the 72 hours after IV administration.